Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous PRAME-targeting TCR-modified T cells MDG1011

Human autologous T lymphocytes transduced with a retroviral vector encoding a human leukocyte antigen (HLA)-A*02:01-restricted T-cell receptor (TCR) specific for the human tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME) coupled to the CD3 signaling complex, with potential antineoplastic activity. Upon reintroduction into the patient, the autologous PRAME-targeting TCR-modified T cells MDG1011 target and bind to tumor cells expressing PRAME. This may induce cell death in and halt the growth of PRAME-expressing tumor cells. The TAA PRAME is overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-PRAME-TCR-expressing T cells MDG1011
autologous PRAME TCR-modified T cells MDG1011
autologous TCR-modified T cells MDG1011
PRAME-TCR gene-modified autologous T cells MDG1011
Code name:MDG 1011
MDG-1011
MDG1011
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search